Stockscreener 앱 받기
60.54
0.39%
-0.2267
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Bristol-Myers Squibb stock rating reiterated by Bernstein at Market Perform - Investing.com India
Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating - TipRanks
Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism - Yahoo Finance UK
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating - Finviz
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence - Yahoo Finance Singapore
Bristol-Myers Squibb Stock Is On Sale: Smart Buy Or Value Trap You’ll Regret? - AD HOC NEWS
Bristol-Myers Squibb Stock: Dividend Giant Under Pressure or Deep-Value Setup? - AD HOC NEWS
Jim Cramer Discusses Bristol Myers's (BMY) Cobenfy Drug - Finviz
Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug - Insider Monkey
Birmingham Capital Management Co. Inc. AL Reduces Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Returns To US$7.1b Trailing Profit Challenging Bearish Narratives - simplywall.st
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim - Investing.com UK
Bristol-Myers Squibb stock price target raised to $60 by Wells Fargo - Investing.com UK
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026 (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb (NYSE:BMY) Given New $64.00 Price Target at Citigroup - MarketBeat
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim By Investing.com - Investing.com India
Bristol-Myers Squibb Co (NYSE:BMY) Tops Estimates - FXDailyReport.Com
Bristol-Myers Squibb Co (BMY) Stock Price Up 3.76% on Feb 6 - GuruFocus
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) | BMY Stock News - GuruFocus
Bristol-Myers Squibb Company (NYSE:BMY) Q4 2025 Earnings Call Transcript - Insider Monkey
Bristol-Myers Squibb Co. (BMY) PT Raised to $72 at Guggenheim - StreetInsider
BMS reports flat revenue growth for full-year 2025 - Pharmaceutical Technology
BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus - Finviz
Bristol Myers Squibb stock gets positive readthrough from Bayer stroke data - Investing.com
Bristol-Myers Squibb (BMY) Exceeds Q4 Earnings Expectations - GuruFocus
Bristol-Myers Squibb (BMY) Surpasses Q4 Expectations, Sets Stron - GuruFocus
Bristol-Myers Squibb (BMY) Reports Strong Q4, Projects Robust Gr - GuruFocus
Why Bristol Myers Squibb Stock Topped the Market Today - Yahoo Finance
Bristol Myers (BMY) Maintains Positive Outlook Amid Stroke Treat - GuruFocus
Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target - TipRanks
Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: Strong Growth in New Products ... By GuruFocus - Investing.com Canada
Bristol's Portfolio of Newer Therapies and Strong Late-Stage Pipeline Support a Wide Moat - morningstar.com
Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: - GuruFocus
Bristol-Myers Squibb (BMY) Surpasses Q4 Expectations and Raises Dividend - GuruFocus
Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising. - Barron's
We're increasing our price target on Bristol Myers after earnings and guidance top forecasts - CNBC
BMS Beats Again Despite Eliquis and Cobenfy Disappointments - BioSpace
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. - Barron's
Bristol-Myers Squibb Q4 2025 slides: Growth portfolio offsets legacy declines - Investing.com
Bristol Myers posts modest Q4 growth, outlines cautious outlook - The Pharma Letter
Earnings call transcript: Bristol-Myers Squibb beats Q4 2025 forecasts By Investing.com - Investing.com India
Earnings call transcript: Bristol-Myers Squibb beats Q4 2025 forecasts - Investing.com
Bristol’s Outlook Tops Views as New Drugs Gain Momentum - Bloomberg.com
Bristol Myers Squibb (NYSE:BMY) Issues FY 2026 Earnings Guidance - MarketBeat
Bristol Myers earnings beat amid blood thinner, cancer immunotherapy strength - Investing.com India
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025 - Finviz
Bristol Myers Squibb Co (NYSE:BMY) Beats Q4 2025 Earnings Estimates and Provides Strong 2026 Outlook - Chartmill
Bristol Myers: Q4 Earnings Snapshot - kens5.com
Bristol Myers earnings beat estimates amid cancer immunotherapy drug strength - Investing.com
Bristol-Myers Squibb earnings beat by $0.14, revenue topped estimates - Investing.com South Africa
Bristol Myers forecasts upbeat 2026, expects Eliquis price cut to pay off - Reuters
Bristol-Myers Stock (BMY) Breaking Out As Earnings Await – What To Expect - AskTraders.com
Alphabet, Amazon And 3 Stocks To Watch Heading Into Thursday - Benzinga
Bristol-Myers Squibb Expands RNA And Cell Therapy Pipeline With New Deals - simplywall.st
1.96%
1.42%
자본화:
|
볼륨(24시간):